Scott L. Burrows - Feb 1, 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/2/2024, 08:27 PM
Previous filing
Dec 22, 2023
Next filing
Sep 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +70K $0.00 70K Feb 1, 2024 Common Stock 70K $25.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option a right to purchase 70,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.